Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety
Gangadaran N et al. Cancer Rep (Hobokken), January 2026 – open access publication
Link to full abstract